Rebetol

This page contains recent news articles, when available, and an overview of Rebetol but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Rebetol (when available)

Pharmacology and use:
Ribavirin is an anti-viral drug active against a number of DNA and RNA viruses. It is a member of the nucleoside antimetabolite drugs that interfere with duplication of the viral genetic material. The drug inhibits the activity of the enzyme RNA dependent RNA polymerase, due to it's resemblence to building blocks of the RNA molecules. The oral form is used in the treatment of hepatitis C, in combination with interferon drugs. The aerosol form is used to treat respiratory syncytial virus-related diseases in children. The primary serious adverse effect of ribavirin is hemolytic anemia, which may worsen preexisting cardiac disease. For the treatment of chronic hepatitis C and for respiratory syncytial virus (RSV)

Mechanism Of Action:
Ribavirin is readily phosphorylated intracellularly by adenosine kinase to ribavirin mono-, di-, and triphosphate metabolites. Ribavirin triphosphate (RTP) is a potent competitive inhibitor of inosine monophosphate (IMP) dehydrogenase, viral RNA polymerase and messenger RNA (mRNA) guanylyltransferase (viral). Guanylyltranserase inhibition stops the capping of mRNA . These diverse effects result in a marked reduction of intracellular guanosine triphosphate (GTP) pools and inhibition of viral RNA and protein synthesis. Ribavirin is also incorporated into the viral genome causing lethal mutagenesis and a subsequent decrease in specific viral infectivity.

News Articles on Ribavirin

Top-Line Results of Boceprevir Phase II Study Showed High Rate of ...  -  Aug 4, 2008
...(1-3) Patients in the study who received 48-weeks of boceprevir in combination with PEGINTRON and REBETOL from the beginning of treatment (no P/R lead-in) CNNMoney.com (press release)

Schering-Plough Reports Positive Results From Phase II Hepatitis Study  -  Aug 5, 2008
Patients in the study who received 48-weeks of boceprevir in combination with Pegintron and Rebetol from the beginning of treatment (no P/R lead-in) RedOrbit,

Schering-Plough reports positive top-line results for hepatitis C ...  -  Aug 4, 2008
Patients in the study who received 48-weeks of boceprevir in combination with Pegintron and Rebetol from the beginning of treatment achieved 66% SVR rate at RTT News,

Health Winners & Losers: Elan  -  Aug 4, 2008
The company said that at 48 weeks, the sustained virologic response (SVR) rate in the boceprevir-combination arm, with patients taking pegintron and rebetol TheStreet.com

Schering-Plough Reports Financial Results for Second Quarter of 2008  -  Jul 21, 2008
212 - - CLARITIN RX 111 102 8% 239 214 11% INTEGRILIN 78 78 - 152 163 (7%) CAELYX 78 65 20% 152 127 20% REBETOL 70 74 (5%) 130 146 (11%) ZEMURON c/ 67 PR Newswire (press release),

Malattie ematologiche: ruolo della Ribavirina nelle infezioni da ...  -  Jul 30, 2008
I pazienti con grave immunodeficienza sono stati trattati con Ribavirina ( Rebetol ), Immunoglobulina per via endovenosa e Palivizumab ( Synagis ), mentre i XagenaSalute,

Vertex drops as rival's hepatitis drug advances  -  May 21, 2008
Both studies will combine boceprevir after four weeks of treatment with two of Schering-Plough's older drugs, Peg-Intron and Rebetol. In the larger trial, Forbes,

Schering-Plough to Initiate Two Phase III Hepatitis Studies  -  May 22, 2008
In both Phase III clinical studies, patients will receive four weeks of treatment with Pegintron and Rebetol prior to the addition of boceprevir. RedOrbit,

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis ...  -  May 15, 2008
The anemia associated with REBETOL therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a Earthtimes (press release),

Valeant to Lay Off Half Its Workforce  -  May 6, 2008
And Viramadine, a replacement drug for Valeant’s hepatitis-C treatment, ribavarin (marketed by Schering-Plough under the name Rebetol), seemed just around PharmExec.com,

Schering-Plough Reports Financial Results for First Quarter of 2008  -  23 Apr 2008
...(Announced March 18) -- Gained FDA approval of label revisions for PEGINTRON (peginterferon alfa-2b) and REBETOL (ribavirin, USP) combination therapy for PR Newswire (press release),

Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR ...  -  Mar 27, 2008
The study showed that PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient body weight) resulted in a significantly higher FOXBusiness

FDA Approvals: Rotarix and PegIntron/Rebetol  -  Apr 10, 2008
...ribavirin (Rebetol) combination therapy, recommending weight-based dosing of ribavirin for the treatment of chronic hepatitis C virus (HCV) infection. Medscape (subscription)

Revised dosing for Pegintron/Rebetol  -  Mar 27, 2008
The FDA has approved label revisions for Schering-Plough’s Pegintron (peginterferon alfa-2b) and Rebetol (ribavirin) combination therapy for chronic Prescribing Reference,

Schering-Plough To Present Data On Chronic Hepatitis C Therapies ...  -  Apr 17, 2008
...(SGP), announced that it would present the final results of the IDEAL study, which evaluated the Pegintron (peginterferon alfa-2b) and Rebetol combination RTT News,

Schering-Plough shares rise on FDA OK  -  Mar 27, 2008
Shares of drug developer Schering-Plough Corp. rose following the Food and Drug Administration's approval of dosing changes for Rebetol in combination with BusinessWeek

The Yin and Yang of Schering's Label Changes  -  Mar 28, 2008
Yesterday, the FDA approved changes to Schering's Rebetol, which is taken in combination with its Pegintron to fight hepatitis C infections. Motley Fool

Drug stocks climb; Schering-Plough, Vertex jump  -  Mar 27, 2008
The drugmaker said that Rebetol's new label will reflect that studies have shown the drug can be more effective when dosed according to patient weight. MarketWatch

Schering-Plough: FDA OKs label revisions for Pengintron, Rebetol ...  -  Mar 27, 2008
Thursday said the Food and Drug Administration has approved label revisions for Pengintron and Rebetol combination therapy for the treatment of chronic Forbes,

Movers Roundup: EBay, Schering-Plough  -  Mar 27, 2008
...following the Food and Drug Administration's approval of dosing changes for Rebetol in combination with Pegintron to treat hepatitis C. NEW YORK (AP) _ CNNMoney.com

Schering Plough (SGP) NewsBite - SGP Rises on FDA Approval  -  Mar 27, 2008
SGP shares are trading higher today after receiving FDA approval for a change on its hepatitis C drug Rebetol that will allow it to be used at higher doses Market Intelligence Center,

Roche Sees Softness in US Hepatitis C Market  -  Apr 21, 2008
...(peginterferon alfa-2b) and Rebetol (ribavirin). Results from the study found sustained virologic responses were similar for the combination therapies. FDA news (subscription),

FDA OKs Label Revisions For Schering-Plough  -  Mar 27, 2008
...(SGP) received approval from the Food and Drug Administration for label revisions on Pegintron and Rebetol combination therapy for chronic hepatitis C. The CNNMoney.com

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data ...  -  Apr 17, 2008
The anemia associated with REBETOL therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a Earthtimes,

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data ...  -  Apr 17, 2008
Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP) combination therapy,(1) as well as a lower dose of PEGINTRON plus REBETOL in an investigational SunHerald.com,

ALSO NOTED: FDA assails King promo for omitted risks; Schering ...  -  Mar 28, 2008
Report > Schering-Plough shares ballooned by 3.2 percent to $19.30 yesterday, on news that the FDA gave its OK to Schering's antiviral drug Rebetol for FiercePharma,

Combining Peginterferon With Weight-Based Ribavirin Increases ...  -  Mar 28, 2008
In WIN-R (Weight-Based Dosing of Pegintron and Rebetol), SVR rates remained consistent with increased body weight for patients receiving weight- based DG News

Southwest Bancorp Q1 Profit Rises - Quick Facts [OKSB]  -  Apr 17, 2008
...that final results of the IDEAL study as well as from several other clinical studies with PEGINTRON or peginterferon alfa-2b and REBETOL or ribavirin, RTT News,

A Drug's Ability To Achieve Sustained Viral Response in Genotype 1 ...  -  Apr 8, 2008
...used in combination with a long-acting interferon-alpha plus ribavirin (Roche's Copegus, Schering-Plough's Rebetol, generics), have advantages in this PR Newswire (press release),

Rebetol Oral Solution  -  Feb 18, 2008
Schering-Plough wishes to announce the launch of Rebetol (ribavirin) 40mg/ml Oral Solution. Rebetol Oral Solution is a clear, colourless to pale or light Irish Medical Times,

SCHERING-PLOUGH CORPORATION - Final Results  -  Feb 12, 2008
5, 2007) -- Gained European Commission approval of PEGINTRON (peginterferon alfa- 2b) and REBETOL (ribavirin) combination therapy for retreating adult Trading Markets (press release),

Schering-Plough Reports Top-Line Results of the IDEAL Study  -  Jan 14, 2008
PEGINTRON was dosed either at 1.5 mcg/kg/week or an investigational combination dose of 1.0 mcg/kg/week with REBETOL at an investigational dose of 800-1400 CNNMoney.com

Roche quick to discount IDEAL trial results  -  Jan 17, 2008
They were randomised to one of three treatment regimens – the two doses of Pegintron plus Rebetol already mentioned, or Pegasys 180 mcg/week plus Copegus Pharma Times (subscription),

First large head-to-head comparison of Schering and Roche HCV ...  -  Jan 16, 2008
The standard daily dose of Rebetol is 800mg, although studies have suggested that increased doses may be more effective. The IDEAL study population Aidsmap,

Pharamcy error causes patient to receive wrong medication  -  Jan 22, 2008
By David Mittleman Gregory Rossini had a liver transplant in 1996 and eventually developed Hepatitis C. He was prescribed Rebetol for his hepatitis C, InjuryBoard.com,

Schering-Plough Hepatitis C Data Positive  -  Jan 15, 2008
Schering-Plough reported results from its Phase IIIb IDEAL trial in hepatitis C patients comparing Pegintron and Rebetol versus Roche’s Pegasys and Copegus. FDA news (subscription),

NYU Med sued in pill mix-up  -  Jan 28, 2008
Dr. Elie Abemayor, the attending physician at the NYU Medical Center's gastroenterology department, said a hypothetical short-term cessation of Rebetol NYU Washington Square News,

Market Report -- In Play (SGP)  -  Jan 14, 2008
...the first large, randomized, clinical study comparing the leading therapies for chronic hepatitis C: PEGINTRON and REBETOL combination therapy vs. MSN Money

Oppenheimer Closes Acquisition Of CIBC World Markets' US Capital ...  -  Jan 14, 2008
In the first large, randomized, clinical study, the company compared therapies for chronic hepatitis C: PEGINTRON and REBETOL combination therapy against RTT News,

Schering-Plough Reports Top-Line Results of the IDEAL Study  -  Jan 14, 2008
...similar for the two leading combination therapies for hepatitis C; and that using a lower dose of PEGINTRON with REBETOL also resulted in a similar SVR. Biloxi Sun Herald,

BRIEFS: PATIENT: I WAS GIVEN WRONG DRUG  -  Jan 10, 2008
18, 2005, when the patient asked for a medication called Rebetol for hepatitis C. The unidentified pharmacist instead gave him Reyataz, an HIV medication, Newsday,

Focus on the Schering-Plough Corporation Company Profile  -  Nov 29, 2007
2006-12 57 Growth drivers 61 Zetia/Vytorin 61 MFF258 62 Asenapine 62 Nasonex 62 Remicade 62 Sugammadex 63 Growth resistors 63 Clarinex 63 Rebetol 64 Reuters

Schering-Plough's Pegintron and Rebetol combination therapy ...  -  Nov 14, 2007
Pegintron and rebetol is the first and only pegylated interferon combination therapy approved in the EU for retreating both hepatitis C relapsers and CNNMoney.com

Schering-Plough Highlights PEGINTRON Clinical Data Presentations ...  -  Oct 30, 2007
Among these are several studies discussing the predictability of response with PEGINTRON and REBETOL and assessing how results at important treatment PharmaLive.com (press release),

Initial Results Of Phase II Study With HCV Protease Inhibitor ...  -  Oct 19, 2007
Boceprevir is being evaluated in combination with PEGINTRON and REBETOL for the treatment of patients chronically infected with hepatitis C virus (HCV) Medical News Today (press release),

AASLD: HCV Outcomes Found Equivalent With Pegylated Interferons ...  -  Nov 4, 2007
4 -- The pegylated interferons alpha-2a (Pegasys) and alpha-2b (pegintron) are comparably effective and safe in combination with ribavirin (Rebetol) for MedPage Today,

Schering-Plough Reports Financial Results for Third Quarter of 2007  -  Oct 22, 2007
In a Phase II study in treatment-naïve hepatitis C patients, boceprevir combination therapy with PEGINTRON and REBETOL achieved a high rate of early PR Newswire (press release),

First Clinical Trial With Investigational Agent Telaprevir Phase ...  -  Nov 11, 2007
...either Pegasys® + Copegus® (peg interferon alfa-2a + ribavirin) or Pegintron™ + Rebetol® (peginterferon alfa-2b + ribavirin), which will be given for at Medical News Today (press release),

AASLD: Telaprevir Yields Good Response in Combo Therapy for HCV  -  Nov 7, 2007
In PROVE1, three groups received telaprevir 750 mg every 8 hours, pegylated interferon alpha 2a (Peg-IFN) 180 μg/week, plus ribavirin (Rebetol) 1000 to 1200 MedPage Today,

Market Report -- In Play (WIRES)  -  Nov 15, 2007
On The Wires Schering-Plough (SGP) announces that the European Commission on October 30 approved 48-week standard-dose PEGINTRON and REBETOL combination MSN Money

CHMP nod for PegIntron/Rebetol combo  -  Sep 25, 2007
PegIntron and Rebetol combination therapy is currently approved in the EU for treatment naïve chronic hepatitis C patients, including those with clinically Pharma Times (subscription),

European Union's CHMP Issues Positive Opinion on PEGINTRON(TM ...  -  Sep 24, 2007
Upon European Commission approval, PEGINTRON and REBETOL will be the only available hepatitis C therapy in the European Union (EU) indicated for retreatment CNNMoney.com

Second-Line Isn't Second Best  -  Sep 26, 2007
It's PEGINTRON and REBETOL combination therapy is already approved as a front-line treatment and there aren't any drugs approved in Europe to treat cases Motley Fool

Committee for Medicinal Products for Human Use Post-Authorisation ...  -  Sep 21, 2007
Adult patients: Rebetol is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have PharmaLive.com (press release),

UPDATE 1-Schering-Plough hepatitis combo gets OK EU opinion  -  Sep 24, 2007
Peg-Intron is approved in the United States as a single agent treatment and for use in combination with Rebetol. Schering-Plough said it tested the Reuters

Schering-Plough:EU's CHMP Recommends Hep C Treatment Approval  -  Sep 24, 2007
...(SGP) said the European Union's Committee for Medicinal Products for Human Use recommended approval of a combination treatment of Pegintron and Rebetol for CNNMoney.com

VRUS: Hits All-Time High After Ph I Dosing Begins for Hepatitis C ...  -  Oct 3, 2007
...of Pegintron(TM)(peginterferon alfa-2b) and Rebetol(R)(ribavirin); Schering's Intron(R) A (Interferon alfa-2b, recombinant) plus Rebetol(R)(ribavirin); Trading Markets,

Meeting Highlights from the Committee for Medicinal Products for ...  -  Sep 21, 2007
Rebetol (ribavirin), from SP Europe, to extend the indication in combination with peginterferon alfa-2b to adult patients who have failed previous treatment PharmaLive.com (press release),

Attention Business And Medical Editors:  -  Aug 27, 2007
...which is used both as a monotherapy and in combination with REBETOL(R) (ribavirin) capsules for the treatment of chronic hepatitis C. Under Enzon's Canada NewsWire (press release),

Schering-Plough Reports Financial Results for Second Quarter of 2007  -  Jul 23, 2007
PR Newswire (press release),...(Announced June 21) - Gained European Commission approval for combination therapy with PEGINTRON (peginterferon alfa-2b) and REBETOL (ribavirin) for the

Schering-Plough's Pegintron, Rebetol Combp Therapy OKed In EU  -  Jun 25, 2007
CNNMoney.com...(SGP) said the European Commission approved combination therapy with Pegintron and Rebetol for the treatment of previously untreated adult patients with

Combination Hepatitis C/HIV Therapy Approved in Europe  -  Jul 2, 2007
FDA news (subscription),1.5 mcg/kg once weekly) and Rebetol (ribavirin, 800–1200 mg daily) to treat previously untreated adult patients with chronic hepatitis C who are

Schering-Plough Gets EU OK for Hep C/HIV  -  Jun 25, 2007
Forbes,The latest approval was based on two clinical studies showing that hepatitis C patients, with HIV, who were given Pegintron and Rebetol had significantly

ViroPharma Announces Enrollment Complete in HCV-796 Phase II Study  -  Jun 12, 2007
FDA news (subscription),...profile and antiviral activity of HCV-796 when used in combination with pegylated interferon alfa-2b (PEG-Intron) plus ribavirin (Rebetol) compared with

ViroPharma Announces Completion of Enrollment in 500mg BID Arms of ...  -  Jun 12, 2007
PR Newswire (press release),...and antiviral activity of HCV-796, when used in combination with pegylated interferon alfa-2b (PEG-Intron(R)) plus ribavirin (REBETOL(R)) compared to

Definitions of not just such overhead tool.  -  Jul 1, 2007
Gazeta Lubuska,Ten months individual body antibody tests while costs rebetol norms. Human neuroscience refore disposable in trialing literature on publisher.

Schering-Plough Announces Hepatitis C Data Presentations At ...  -  May 19, 2007
Medical News Today (press release),This second cohort will evaluate the safety and efficacy of boceprevir in combination with PEGINTRON and a lower dose of REBETOL (400-1000 mg daily).

Committee for Medicinal Products for Human Use Post-authorisation ...  -  Apr 27, 2007
PharmaLive.com (press release),Adult patients: Rebetol is indicated, in combination with peginterferon alfa-2b, for the treatment of adult patients with chronic hepatitis C,

Schering-Plough (SGP) Announces Hepatitis C Data Presentations  -  May 18, 2007
StreetInsider.com (subscription),A total of 20 oral and poster presentations on clinical studies with Schering-Plough's (NYSE: SGP)hepatitis products, including PEGINTRON and REBETOL

Market Report -- In Play (WIRES)  -  Apr 30, 2007
MSN MoneyPEGINTRON and REBETOL for the treatment of previously untreated adult patients with chronic hepatitis C who are coinfected with clinically stable HIV.

Schering-Plough presenting Hepatitis C at Digestive Disease Week ...  -  May 19, 2007
SpiritIndia,...including PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for chronic hepatitis C virus (HCV) infection,

Brand Names/Synonyms:
Rebetol is also known by the following brand names and/or synonymsBiopolymers; Copegus; DRG-0028; HSDB 6513; ICN 1229; ICN-1229; RBV; RIBAV; RTC; RTCA; RTP; Rebetol; Rebetron; Rebretron; Ribamide; Ribamidil; Ribamidyl; Ribasphere; Ribavirin; Ribavirin Capsules; Ribavirin Triphosphate; Ribavirin [Usan:Inn]; Ribavirin-Tp; Ribavirina [Inn-Spanish]; Ribavirine; Ribavirine [Inn-French]; Ribavirinum [Inn-Latin]; Tribavirin; Varazid; Vilona; Viramid; Virazid; Virazole; Virazole 5'-Triphosphate

Drug Category:
Rebetol is categorized under the following by the FDA: Antiviral; ATC:J05AB04

Dosage Forms:
Inhalation solution, Tablets

Absorption:
Ribavirin was rapidly and extensively absorbed following oral administration. However, due to first-pass metabolism, the absolute bioavailability averaged 64% (44%).

Interactions:
[an error occurred while processing this directive]

Chemical IUPAC Name:
1-[3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-1,2,4-triazole-3-carboxamide

:

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.